27th week of 2011 patent applcation highlights part 30 |
Patent application number | Title | Published |
20110165025 | STOPPED-FLOW CHIP - A chip for performing and measuring chemical reactions, interactions (bonds), and/or conformational changes, especially fast chemical reactions and processes. The chip includes a base plate, which is made of a polymer material that is transparent at least in the measuring zone, and having. fluid ducts parallel to the plane of the base plate and includes at least two reagent feeders leading into a mixer structure that has a number of inlets corresponding to the number of reagent feeders and an outlet leading into a mixing section, the outlet of the mixing section leads into a measuring section, the outlet of the measuring section is connected to a discharge section, the discharge section leads out of the base plate or into a reservoir that is arranged on the chip, and pressure conduits lead into the reagent feeders at a distance from the mixer structure. | 2011-07-07 |
20110165026 | SYSTEM FOR MAINTAINING FLAME STABILITY AND TEMPERATURE IN A CLAUS THERMAL REACTOR - A system may include a sulfur recovery unit. The sulfur recovery unit may include an acid gas supply, which may supply acid gas, an oxygen supply, which may supply oxygen, a fuel supply, which may supply fuel. The fuel may have a higher heating value than the acid gas. Also, the sulfur recovery unit may include a thermal reaction zone, which may thermally recover sulfur from the acid gas by combustion of the fuel and the acid gas with the oxygen and through reaction of the acid gas with combustion products arising from the combustion. | 2011-07-07 |
20110165027 | METHOD AND APPARATUS FOR CURING WASTE CONTAINING PHOTOPOLYMERIC COMPONENTS - An Apparatus for polymerizing photoactive materials included in a liquid material by electromagnetic radiation, by dispensing the liquid material layer-wise into a container and irradiating the accumulated layers by a curing radiation, wherein a substantial part of the radiation is well transmitted through the photoactive material. | 2011-07-07 |
20110165028 | METHOD FOR PURIFICATION OF SILICA PARTICLES, PURIFIER, AND PURIFIED SILICA PARTICLES - [Problems] To provide a treatment method having excellent purification effect, in which impurities having high ionicity in a silica powder can be removed in a short time, a apparatus thereof, and a purified silica powder. | 2011-07-07 |
20110165029 | SLURRY BED LOOP REACTOR AND USE THEREOF - The present invention relates to a slurry bed loop reactor comprising a riser and at least one downcomer ( | 2011-07-07 |
20110165030 | INTERNAL RESISTIVE HEATING OF CATALYST BED FOR MONOPROPELLANT CATALYST - Catalyst beds for monopropellant propulsion systems are heated by resistance heating through a conductive material that is incorporated in the catalyst bed and a pair of electrodes on opposite sides of the bed. Imposition of a voltage across the electrodes to heat the bed is performed at will without consumption of any heating components, and heating of the bed is achieved rapidly and uniformly across the entire bed. | 2011-07-07 |
20110165031 | DEVICE FOR PERFORMING CHEMICAL AND/OR PHYSICAL REACTIONS BETWEEN A SOLID MATERIAL AND A GAS - The device according to the invention for performing chemical and/or physical reactions between a solid material and a gas, especially for preheating, cooling and/or calcining fine-grained materials has at least three stages arranged one above the other, each stage comprising the following components: a. a gas-solids suspension duct for conducting a gas-solids suspension, b. means for separating the delivered solid material from the delivered gas, c. a solids duct for discharging the separated solid material, d. and a gas duct for discharging the separated gas, the gas duct of one stage merging into the gas-solids suspension duct of the next-higher stage and the solids duct of one stage joining the gas-solids suspension duct of the next-lower stage. In addition, the junction of the solids duct and the gas-solids suspension duct of the third or a higher stage is provided below the highest point of the gas-solids suspension duct arranged two stages lower. | 2011-07-07 |
20110165032 | PRODUCTION PROCESS FOR HIGH PURITY POLYCRYSTAL SILICON AND PRODUCTION APPARATUS FOR THE SAME - In the production process of the present invention for high purity polycrystal silicon, using a vertical reactor having a silicon chloride gas-feeding nozzle and a reducing agent gas-feeding nozzle which are disposed at an upper part and a waste gas discharge pipe, a silicon chloride gas and a reducing agent gas are fed into the reactor to form polycrystal silicon at a tip part of the silicon chloride gas-feeding nozzle by the reaction of the silicon chloride gas with the reducing agent gas, and the polycrystal silicon is allowed to grow from the tip part of the silicon chloride gas-feeding nozzle toward a lower part thereof. | 2011-07-07 |
20110165033 | COMPONENT MADE OF A STACK OF CERAMIC PLATES - The invention relates to a component comprising a plurality of plates ( | 2011-07-07 |
20110165034 | IMPACT LOAD PROTECTION FOR MASS-BASED PRODUCT DISPENSERS - A chemical product dispenser that controls dispensation of a chemical product based on a change in weight of the chemical product remaining in the dispenser includes an isolation mechanism. The dispenser includes a weight measurement instrument, such as one or more load cells, that measure the weight of the chemical product remaining the dispenser. The isolation mechanism is configured to lift the chemical product from a lowered position in which the weight of the chemical product is fully supported by the load cell(s) to a raised position in which the weight of the chemical product is fully supported by the isolation mechanism. When in the raised position, the dispenser may be loaded with a supply of chemical product with a reduced risk of damage to the weight measurement instrument. | 2011-07-07 |
20110165035 | Waste treatment apparatus and method - An apparatus for treating waste comprises a gravity drop steam heating tower for heating the waste to the biological kill temperature using pressurized steam, a first feed member for feeding the waste to be sterilized to the gravity drop steam heating tower, and a vaporization system. The vaporization system includes a heating chamber for facilitating vaporization of liquids in the waste, a conveying member for conveying the waste from the lower end portion of the gravity drop steam heating tower into and through the heating chamber, and a vaporization chamber for receiving the waste from the heating chamber and for releasing vapor entrained in the waste into the vaporization chamber. | 2011-07-07 |
20110165036 | AUTOMATIC PHYSIOLOGICAL ASSAY DEVICE - An automatic physiological assay device analyzes light reflected by an assay device and prevents ambient light from interfering with the assay device. The automatic physiological assay device in accordance with the present invention comprises a chassis, an assay device connector assembly, an assay device and a light detecting device. The chassis comprises closed bottom, multiple sidewalls, an inner cavity, an open top and a removable top cover. The assay device connector assembly is mounted slidably through a sidewall and comprises an outer end, two sides and a cover. The cover is mounted on the outer end, seals the sidewall and keeps ambient light away from the assay device. The light detecting device is mounted in the inner cavity and on top edges of guides adjacent the assay device connector assembly. | 2011-07-07 |
20110165037 | INTERFACES THAT ELIMINATE NON-SPECIFIC ADSORPTION, AND INTRODUCE SPECIFIC INTERACTIONS - A microfluidic system comprising a microchannel, a carrier fluid comprising a fluorinated oil in the microchannel, at least one plug comprising an aqueous plug-fluid in the microchannel and substantially surrounded on all sides by the carrier-fluid, and a fluorinated surfactant comprising a functional group capable of selectively binding a target molecule is disclosed. A compound for use therewith and a method of synthesizing a fluorinated surfactant are also provided. | 2011-07-07 |
20110165038 | USE OF AUTOLOGOUS SEDIMENT FROM FLUID ASPIRATES AS VEHICLES FOR DRUG DELIVERY - A centrifuge tube apparatus for centrifuging a sample collected in a syringe, the apparatus comprising: a syringe comprising at one end a narrowed outlet and means for connection to a needle and at the opposing end a partially inserted syringe plunger; and a syringe holder having an interior for accepting the syringe, wherein the interior comprises at least one ledge for resting the syringe in an inverted position within the holder to prevent further insertion of the plunger during centrifugation, further wherein the syringe holder is sized for insertion in a centrifuge rotor. | 2011-07-07 |
20110165039 | SPECIMEN CONTAINER - A specimen container ( | 2011-07-07 |
20110165040 | DEVICE FOR REMEDIATING EMISSIONS AND METHOD OF MANUFACTURE - In at least one embodiment, a combined selective catalytic reduction catalyst and particulate filter (SCRF) includes a particulate filter having walls defining an intake channel including a downstream end cap and an outlet channel including an upstream end cap and an open end through which emissions pass. The walls define a plurality of pores. The walls include a plurality of zeolite-base metal particles and a binder. A washcoat is situated adjacent to less than 50% of the length of the outlet channel. The washcoat is capable of receiving noble metal particles. | 2011-07-07 |
20110165041 | PROCESSESS FOR THE RECOVERY OF RUTHENIUM FROM MATERIALS CONTAINING RUTHENIUM OR RUTHENIUM OXIDES OR FROM RUTHENIUM-CONTAINING NOBLE METAL ORE CONCENTRATES - Processes for the recovery of ruthenium from materials containing ruthenium or ruthenium oxides or from ruthenium-containing noble metal ore concentrates, with the steps of
| 2011-07-07 |
20110165042 | INTEGRATED BOILER AND AIR POLLUTION CONTROL SYSTEMS - An air pollution control system includes an emission treatment system configured to receive flue gas, to reduce at least one pollutant therefrom, and to output emission treated flue gas. A first air heater in fluid communication with the emission treatment system includes a heat exchanger for heating forced air introduced thereto above a base temperature and thereby cooling emission treated flue gas from the emission treatment system to a stack discharge temperature. A second air heater in fluid communication with the first air heater to receive heated forced air therefrom includes a heat exchanger for heating forced air introduced thereto to a preheat temperature for combustion in a boiler and thereby cooling flue gas introduced from a boiler to the second air heater to an emission treatment temperature. The second air heater is in fluid communication with the emission treatment system to introduce cooled flue gas thereto. | 2011-07-07 |
20110165043 | METHOD FOR PURIFYING EXHAUST GAS CONTAINING MERCURY METAL, OXIDATION CATALYST FOR MERCURY METAL IN EXHAUST GAS AND METHOD FOR PRODUCING THE SAME - Provided are a catalyst for removing mercury metal, which has high activity for a long time even in an exhaust gas containing SO | 2011-07-07 |
20110165044 | BROMINE CHLORIDE COMPOSITIONS FOR REMOVING MERCURY FROM EMISSIONS PRODUCED DURING FUEL COMBUSTION - Compositions, and processes utilizing such compositions, are provided for reducing mercury emissions during fuel combustion Such compositions comprise a sorbent, a bromine source and a chlorine source Such compositions exhibit improved thermal stability as compared to that of the sorbent by itself. | 2011-07-07 |
20110165045 | EXHAUST GAS PURIFICATION CATALYS AND METHOD FOR PURIFYING GAS BY USING SAME - An exhaust gas purification catalyst of the present invention contains at least a precious metal coated with lanthanum-containing alumina. In at least one embodiment, it is possible to provide: an exhaust gas purification catalyst which can (i) have an increase in heat resistance, and (ii) inhibit the precious metal from being mixed in alumina and therefore inhibit the precious metal from forming a solid solution in combination with alumina; and a method for efficiently purifying, by use of the catalyst, an exhaust gas emitted from an internal-combustion engine. | 2011-07-07 |
20110165046 | System For Remediating Emissions And Method of Use - One aspect of the present invention relates to a system for remediating emissions using a hybrid oxidation catalyst system. The hybrid oxidation catalyst system includes a noble metal oxidation catalyst having noble metal particles in a first ceramic layer. The system also includes a base metal oxide catalyst disposed in a second ceramic layer situated downstream of the noble metal oxidation catalyst. The noble metal oxidation catalyst is effective to substantially prevent hydrocarbon or carbon monoxide inhibition of the base metal oxide catalyst when enhancing the NO+O | 2011-07-07 |
20110165047 | SULFIDE SCAVENGING PROCESSES - Processes directed to the removal of sulfurous compounds from air are presented herein. The compositions and processes may be able to treat air with H | 2011-07-07 |
20110165048 | METHOD OF TREATING NITROGEN OXIDE-CONTAINING GAS - First, the emission amount of nitrogen oxides can be decreased close to zero as much as possible, and the emission amount of carbon monoxide is decreased to a permissible range. Second, energy saving by combustion at a low air ratio close to 1.0 is realized. Third, air ratio control is performed stably in a combustion region at a low air ratio. | 2011-07-07 |
20110165049 | CATALYST FOR REMOVAL OF NTROGEN OXIDES FROM EXHAUST GAS, METHOD OF PREPARING THE SAME AND METHOD OF REMOVING NITROGEN OXIDES USING THE SAME FROM EXHAUST GAS - The present invention relates to a catalyst for removal of nitrogen oxides from exhaust gas, a method of preparing the same and a method of removing nitrogen oxide in an exhaust gas using the same, and more particularly, to a catalyst for removal of nitrogen oxides from exhaust gas in which a ceramic fiber carrier is hydrothermal-treated prior to washcoating to improve the hydrothermal stability of catalyst, a method of preparing the same and a method of removing nitrogen oxide in an exhaust gas using the same. | 2011-07-07 |
20110165050 | Sealing of no compressor and residaul gas expander in a nitric acid plant - A process for sealing the NO compressor and the residual gas expander in a plant for the production of nitric acid by the dual-pressure process uses a low-pressure section, a NO compressor, a high-pressure section with oxidation and absorption, at least one heat exchanger, a residual gas expander, in which ammonia and compressed air are passed into the low-pressure section of the nitric acid plant, where ammonia is oxidised via a catalyst to yield NO and water. The obtained NO is partly oxidised to yield NO | 2011-07-07 |
20110165051 | Process Of Direct Copper Exchange Into Na+-Form Of Chabazite Molecular Sieve, And Catalysts, Systems And Methods - Disclosed are processes for the preparation of copper containing molecular sieves with the CHA structure wherein the copper is exchanged into the Na | 2011-07-07 |
20110165052 | Process for Preparation of Copper Containing Molecular Sieves With the CHA Structure, Catalysts, Systems and Methods - Disclosed are processes for the preparation of copper containing molecular sieves with the CHA structure having a silica to alumina mole ratio greater than about 10, wherein the copper exchange step is conducted via wet state exchanged and prior to the coating step and wherein in the copper exchange step a liquid copper solution is used wherein the concentration of copper is in the range of about 0.001 to about 0.25 molar using copper acetate and/or an ammoniacal solution of copper ions as copper source. Catalysts made by the processes, catalyst systems and methods of treating exhaust gas with the molecular sieves and catalysts are also disclosed. | 2011-07-07 |
20110165053 | METHODS OF PREPARING CLUSTERBORON - The invention provides new methods for synthesis of ClusterBoron® (B | 2011-07-07 |
20110165054 | METHOD FOR PURIFICATION OF SILICA PARTICLES, PURIFIER, AND PURIFIED SILICA PARTICLES - [Problems] To provide a treatment method having excellent purification effect, in which impurities having high ionicity in a silica powder can be removed in a short time, a apparatus thereof, and a purified silica powder. | 2011-07-07 |
20110165055 | SYSTEM AND METHOD FOR AMMONIA SYNTHESIS - Systems and methods are disclosed herein for synthesizing ammonia using nano-size metal or metal alloy catalyst particles. Hydrogen and nitrogen gases are passed through a system comprising, for example, a bed of magnetite supporting nano-size iron or iron alloy catalyst particles having an optional oxide layer that forms the catalyst. | 2011-07-07 |
20110165056 | METHOD AND SYSTEM FOR PROCESSING GASEOUS EFFLUENTS FOR INDEPENDENTLY PRODUCING H2 AND CO - A method for the treatment of a first gaseous effluent including carbon dioxide and of a second gaseous effluent including steam, the method includes the following stages: generation of a first gas stream having carbon monoxide by passing the first gaseous effluent through a first layer of redox reactive material including high-temperature carbon components; generation of a second gas stream essentially including dihydrogen by passing the second gaseous effluent through a second redox layer of reactive material including high-temperature carbon components; and utilization of at least one of the first and second gas streams; at least some of the second redox layer being provided by transfer or recovery of at least some of the high-temperature carbon components of the first layer. | 2011-07-07 |
20110165057 | PLASMA CVD DEVICE, DLC FILM, AND METHOD FOR DEPOSITING THIN FILM - To provide a plasma CVD device capable of increasing voltage V | 2011-07-07 |
20110165058 | Growth of Single-walled Carbon Nanotubes - A method for synthesizing carbon nanotubes having a narrow distribution of diameter and/or chirality is presented. The method comprises providing catalyst particles to a reactor for synthesizing the carbon nanotubes, wherein the catalyst particles are characterized by a narrow distribution of catalyst-particle diameters and a narrow distribution of catalyst-particle compositions. Preferably, the catalyst particles are characterized by a mean catalyst-particle diameter of 2.6 nm or less and a composition of Ni | 2011-07-07 |
20110165059 | PRODUCTION OF ZINC SULPHATE CONCENTRATES FROM A DILUTE ZINC SULPHATE SOLUTION - In an embodiment, the present invention relates to an apparatus and a process for producing a concentrated form of basic zinc sulphate from a, typically dilute, acidic zinc sulphate-bearing solution. The process embodiment comprises the steps of precipitating the zinc, preferably primarily as basic zinc sulphate, from the acidic zinc sulphate solution, preferably using calcium oxide, in such a way as to promote the formation of separate gypsum crystals and basic zinc sulphate particles, and upgrading the zinc content in the precipitates by separating the basic zinc sulphate from the gypsum using size separation techniques. | 2011-07-07 |
20110165060 | METAL-FUELED COGENERATION PLANT - A metal-fueled cogeneration plant, comprising at least one reaction chamber, elements for introducing at least one water-based liquid oxidizer, and elements for supplying at least one metal-based fuel into the chamber, the oxidizer and the fuel being adapted to give rise to an exothermic oxidation reaction to obtain gaseous hydrogen and at least one metallic oxide. The introduction elements are adapted to introduce in the chamber a quantity of oxidizer that is substantially greater than the stoichiometric quantity to form steam and comprises at least one fluid-based motive power unit that is fed in input by at least the steam for the rotary actuation of a driving shaft, separation and recovery elements for at least the steam being interposed between the chamber and the inlet to the motive power unit, and elements for evacuation of the hydrogen being further provided. | 2011-07-07 |
20110165061 | METHOD OF ENHANCING THERMAL CONDUCTIVITY IN HYDROGEN STORAGE SYSTEMS - A system for reversibly storing hydrogen includes a storage tank with an internal volume with a thermally conducting composite material situated within the storage tank and having a three-dimensional and interconnected framework of a conductive metal within the internal volume of the storage tank. | 2011-07-07 |
20110165062 | Use of an anti-cd151 antibody for early treatment of cancer - The present invention relates to the use of at least one antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and thereby inhibiting tumour growth, in the preparation of a medicament intended for the early treatment of cancer. | 2011-07-07 |
20110165063 | IL-1 BINDING PROTEINS - The present invention describes IL-1α binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1α. Binding proteins of the invention have high affinity for IL-1α and neutralize IL-1α activity. A binding protein of the invention can be a full-length antibody or an IL-1α-binding portion thereof. Methods of making and methods of using the binding proteins of the invention are also described. The IL-1α binding proteins of the invention are useful for detecting IL-1α and for inhibiting IL-1α activity, including in a human subject suffering from a disease or disorder in which IL-1α activity is detrimental. | 2011-07-07 |
20110165064 | METHODS AND COMPOSITIONS RELATED TO CLOT-BINDING COMPOUNDS - Disclosed are compositions and methods related to clot-binding compounds. For example, disclosed are compositions comprising a surface molecule and at least one modified clot-binding compound. The modified clot-binding compound can selectively bind to clotted plasma protein, wherein the composition causes clotting and amplifies the accumulation of the composition in tumors. The modified clot-binding compound can enhance the clotting in tumors compared to its unmodified derivative. The disclosed targeting is useful for treatment of cancer and other diseases and disorders. | 2011-07-07 |
20110165065 | MEANS FOR THE DETECTION AND TREATMENT OF PROSTATE CELLS - The present invention relates to a composition for the detection and the treatment of prostate cells and to methods for the diagnostic and therapeutic treatment of a human being using the composition according to the invention. | 2011-07-07 |
20110165066 | INTERLEUKIN-13 BINDING PROTEINS - The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental. | 2011-07-07 |
20110165067 | CARBOHYDRATE FUNCTIONALIZED CATANIONIC SURFACTANT VESICLES FOR DRUG DELIVERY - Carbohydrate functionalized catanionic vesicles that include a glycoconjugate and/or peptidoconjugate for vaccination or drug delivery, methods for forming these, and methods of using these. | 2011-07-07 |
20110165068 | Liposome medicament, method of preparation and use thereof - This invention relates to a liposome medicament, and, more particularly, a liposome medicament with targeting function. The liposome medicament includes a medicament that is encapsulated in a liposome, and the medicament contains an effector molecule or an effector molecule that is combined with a first ligand, and a second ligand that is connected onto the surface of the liposome. The first ligand and/or the second ligand can specifically bind to target tissues or target cells to be treated. Preferably, the first ligand and/or the second ligands are antibodies, such as monoclonal antibodies. This invention also relates to a method of preparation of the liposome medicament and use of the medicament for treatment of diseases especially tumors. This invention further relates to a pharmaceutical composition of the liposome medicament and a pharmaceutically acceptable carrier. | 2011-07-07 |
20110165069 | METHODS FOR RADIOLABELING MACROMOLECULES - The present invention relates to a method for preparing a radiolabeled macromolecule, the method comprising contacting a macromolecule with a carbon encapsulated nanoparticle composite having a radioactive particulate core in an aqueous medium comprising a pH selected to promote short-range attractive forces between the nanoparticles and the macromolecule by attenuating repulsive electrostatic forces. | 2011-07-07 |
20110165070 | METHODS FOR RADIOLABELING SYNTHETIC POLYMERS - The present invention relates to a method for preparing a radiolabeled synthetic polymer, the method comprising contacting a synthetic polymer with a carbon encapsulated nanoparticle composite having a radioactive particulate core in an aqueous medium comprising an electrolyte concentration or pH selected to promote short-range attractive forces between the nanoparticles and the synthetic polymer by attenuating long-range electrostatic repulsive forces. | 2011-07-07 |
20110165071 | Methods Of Treating Cancer - Disclosed are methods of treating subjects having cancers including administering an effective amount of an early activation molecule agonist, antagonist or depletor, to the subject. Human monoclonal antibodies specific to the early activation molecules, and methods of use, are also disclosed. | 2011-07-07 |
20110165072 | Detection of Early-Stage Pancreatic Adenocarcinoma - Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The subject antibodies show a number of novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. In preferred embodiments, the antibodies bind to pancreatic cancer mucins. The antibodies and fragments are of use for the detection and diagnosis of early stage pancreatic cancer. In preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay can detect a marker for early stage pancreatic cancer in serum. More preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay. | 2011-07-07 |
20110165073 | IMMUNOTHERAPY OF B-CELL MALIGNANCIES USING ANTI-CD22 ANTIBODIES - B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies. | 2011-07-07 |
20110165074 | CHELATING AMPHIPHILIC POLYMERS - Described are amphiphilic polymers that are provided with chelating moieties. The amphiphilic polymers are block copolymers comprising a hydrophilic block and a hydrophobic block, with the chelating moieties linked to the end-group of the hydrophilic block. The disclosed polymers are capable of self-assembly into structures such as micelles and polymersomes. With suitable metals present in the form of coordination complexes with 5 the chelating moieties, the chelating amphiphilic polymers of the invention are suitable for use in various imaging techniques requiring metal labeling, such as MRI (T | 2011-07-07 |
20110165075 | INTEGRIN TARGETING AGENTS AND IN-VIVO AND IN-VITRO IMAGING METHODS USING THE SAME - The invention provides a family of agents that target integrins, which can be used as imaging agents and/or therapeutic agents. The agents can be used to image angiogenesis, inflammation or other physiological processes in a subject. | 2011-07-07 |
20110165076 | NOVEL [F-18]- LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), USE THEREOF AND METHOD FOR THEIR PRODUCTION - What is described are the compounds and the synthesis of [F-18]-labelled L-glutamic acid, [F-18]-labelled L-glutamate, their derivatives of the formula (I) and their use. | 2011-07-07 |
20110165077 | IN VIVO TUMOR TARGETING AND SPECTROSCOPIC DETECTION WITH SURFACE ENHANCED RAMAN NANOPARTICLE TAGS - Nanostructures, methods of preparing nanostructures, methods of detecting targets in subjects, and methods of treating diseases in subjects, are disclosed. An embodiment, among others, of the nanostructure includes a metallic gold surface-enhanced Raman scattering nanoparticle, a Raman reporter and a protection structure. The protection structure may include a thiol-polyethylene glycol to which may be attached a target-specific probe. | 2011-07-07 |
20110165078 | SPECIFIC BINDING MEMBERS AGAINST SYNAPTOPHYSIN - The present invention provides specific binding members that bind synaptophysin and which comprise: an antibody VH domain selected from the group consisting of the C1-3 VH domain (SEQ ID NO. 2) and a VH domain comprising a VH CDR3 with the amino acid sequence of SEQ ID NO. 12 and optionally one or more VH CDR's with an amino acid sequence selected from SEQ ID NO. 10 and SEQ ID NO. 11; and/or an antibody VL domain selected from the group consisting of the C1-3 VL domain (SEQ ID NO. 4) and a VL domain comprising one or more VL CDR's with an amino acid sequence selected from SEQ ID NO. 13, SEQ ID NO. 14 and SEQ ID NO. 15. The invention further provides related materials such as nucleic acids, kits and compositions, and also methods of use of the binding member, for instance in targeting entities to hepatic stellate cells which are implicated in liver fibrosis. | 2011-07-07 |
20110165079 | PEPTIDE FOR TRANSMIGRATION ACROSS BLOOD BRAIN BARRIER AND DELIVERY SYSTEMS COMPRISING THE SAME - An isolated peptide including an amino acid sequence of SEQ ID NO: 1 is provided. The disclosure also provides a delivery system comprising a carrier having a surface, a drug or a dye encapsulated in the carrier, and the disclosed peptide (having an amino acid sequence of SEQ ID NO: 1) grafted on the surface of the carrier. | 2011-07-07 |
20110165080 | MONOCLONAL ANTIBODIES AND THEIR USE - Isolated monoclonal antibodies are disclosed herein that specifically bind a cell surface antigen expressed on the human pancreatic endocrine cells or a subset thereof, and/or a precursor thereof. Isolated monoclonal antibodies are also disclosed herein that specifically bind a cell surface antigen expressed on human pancreatic exocrine cells or human ductal cells. Humanized forms of these antibodies, and functional fragments of these antibodies, are also disclosed. The antibodies can be conjugated to an effector molecule, such as a detectable marker, a therapeutic agent, or a toxin. These antibodies are of use to detect and isolate pancreatic cells or a subset thereof. The antibodies can be used for in vitro or in vivo detection and/or isolation of pancreatic endocrine cells. Methods of treating a pancreatic tumor are also disclosed. In several examples, the isolated monoclonal antibodies bind pancreatic endocrine cells and can be used to detect diabetes or a pancreatic endocrine cell tumor. | 2011-07-07 |
20110165081 | PSMA ANTIBODIES AND USES THEREOF - The invention includes stable multimeric, particularly dimeric, forms of PSMA protein, compositions and kits containing dimeric PSMA protein as well as methods of producing, purifying and using these compositions. Such methods include methods for eliciting or enhancing an immune response to cells expressing PSMA, including methods of producing antibodies to dimeric PSMA, as well as methods of treating cancer, such as prostate cancer. | 2011-07-07 |
20110165082 | METHOD FOR DETERMINING THE ANTI-TUMOR EFFICACY OF MONOCLONAL ANTIBODIES - The present invention relates to a method for determining the anti-tumor efficacy of monoclonal antibodies in pre-clinical rodent testings and the use of said method for the reduction of side testings. | 2011-07-07 |
20110165083 | Peptides that home to tumor lymphatic vasculature and methods of using same - The present invention provides a conjugate containing a moiety linked to a homing molecule that selectively homes to tumor lymphatic vasculature. The invention also provides a method of directing a moiety to tumor lymphatic vasculature in a subject by administering to the subject a conjugate containing a moiety linked to a homing molecule that selectively homes to tumor lymphatic vasculature. | 2011-07-07 |
20110165084 | VIVO DETECTION OF PHOSPHOLIPASE ACTIVATION - The present invention is directed to a phospholipid-based NIR molecular beacon, having a phospholipid moiety; with an NIR fluorophore moiety covalently linked to a phospholipid glycerol backbone and a quencher moiety covalently linked to the phospholipid glycerol backbone. Additionally, provided herein is methods of analyzing a sample for the presence of a phospholipase and methods of identifying the activity of a phospholipase in vivo utilizing phospholipid-based NIR molecular beacon. | 2011-07-07 |
20110165085 | TUMOR SELECTIVE FLUORESCENT STAINING AGENT - A tumor cell or tumor tissue-selective fluorescent staining agent comprising a compound represented by the following general formula (I): | 2011-07-07 |
20110165086 | IRON OXIDE NANOPARTICLES AS MRI CONTRAST AGENTS AND THEIR PREPARING METHOD - Iron oxide nano contrast agents for Magnetic Resonance Imaging which have superior T | 2011-07-07 |
20110165087 | TARGETED DELIVERY OF IMAGING PROBES FOR IN VIVO CELLULAR IMAGING - The present invention relates to nitroxide imaging probes that are isotopically modified or unmodified. Such nitroxide imaging probes may be included in liposomes that encapsulate self-quenching concentrations thereof, wherein the liposomes optionally comprise a targeting ligand specific to and having affinity for targeted tissue. | 2011-07-07 |
20110165088 | NANOBUBBLES USEFUL AS AN ULTRASONIC CONTRAST AGENT FOR LYMPHATIC SYSTEM - A composition is provided accompanying nonoparticles having diameters in the range of about 100 to 800 nanometers with hollow cores and outer shells with mechanical properties such that they rupture on exposure to predetermined ultrasound energy. The composition is useful for identifying sentinel lymph nodes. | 2011-07-07 |
20110165089 | Complex Compound and MRI Probe Made of Same - Novel gadolinium complex compounds responsive to ions and compounds other than zinc ion, as well as MRI probes made of the compounds are disclosed. Since the gadolinium complex compounds of the present invention such as that represented by the following structural formula exhibit responsiveness to potassium ion, calcium ion, glucose or the like, by using the gadolinium complex compounds of the present invention as a MRI probe, the ion or compound in a living body can be detected and concentration distribution thereof may be determined. | 2011-07-07 |
20110165090 | METHOD AND COMPOSITION FOR DELIVERY OF MEDICANTS TO ANIMALS - According to the present invention, a vaccine or pharmaceutical-containing composition is applied to the muzzle area of the animal, which will then naturally use its tongue to clean itself. This behavior will cause the animal to deposit applied composition to the mucosa of the nasal and oral cavities, thus meeting the need for a simple, effective, and efficient vaccination or treatment method. | 2011-07-07 |
20110165091 | METHOD AND COMPOSITION FOR DELIVERY OF MEDICANTS TO ANIMALS - According to the present invention, a vaccine or pharmaceutical-containing composition is applied to the muzzle area of the animal, which will then naturally use its tongue to clean itself. This behavior will cause the animal to deposit applied composition to the mucosa of the nasal and oral cavities, thus meeting the need for a simple, effective, and efficient vaccination or treatment method. | 2011-07-07 |
20110165092 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION - The subject matter of the invention is a cosmetic and/or dermatological composition for use in the treatment of skin and/or hair disorders. More particularly, the invention relates to a cosmetic and/or dermatological composition comprising an inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, an inhibitor of farnesyl pyrophosphate synthase, or an inhibitor of one of the physiologically acceptable salts thereof and a cosmetic and/or dermatological product. The present invention finds, for example, a very advantageous use in the treatment of the effects of early ageing, in particular in terms of the skin and the hair system. | 2011-07-07 |
20110165094 | USE OF VITAMIN E OR DERIVATIVES THEREOF FOR THE CONTROL OF ARTHROPODS - The use of a composition containing vitamin E or a derivative thereof in a vehicle comprising a volatile siloxane for the control of arthropods, in particular ectoparasites such as lice, is described; the composition may be delivered by means of a spray delivery device or may be in the form of a hydrophobic gel. | 2011-07-07 |
20110165095 | COMPOSITION AND METHOD FOR THE INHIBITION OF POSTOPERATIVE ADHESIONS SEVERITY - The present invention refers to the use of growth factors, which are effective on mesothelial cell proliferation, used in a sterilized carboxymethylchitosan pharmaceutical composition employed to reduce postoperative adhesions severity. The present invention also provides a method to inhibit postoperative adhesions severity. | 2011-07-07 |
20110165096 | Ficus Extracts Having Angiogenesis Ihibiting Activity And Methods Of Isolating And using The Same - The present invention is directed to methods for extracting and isolating extracts having angiogenesis inhibiting activity from a latex-containing portion of a | 2011-07-07 |
20110165097 | COMPOSITIONS FOR PERCUTANEOUS ADMINISTRATION - Compositions intended for the percutaneous administration of physiologically active agents, e.g. drugs or a veterinary agents, are disclosed. Sasd compositions are characterized by having an exeefenf long term efficacy due to their ability to form a long-lasting film on the skin. | 2011-07-07 |
20110165098 | METHODS TO PREVENT CYTOTOXICITY USING N-ACETYL-CYSTEINE - Compositions and methods to inhibit adverse physiological effects caused by resin-based and resin-containing materials are disclosed. More specifically, the use of N-acetyl-cysteine (NAC) to inhibit hydroxyethyl methacrylate (HEMA)-mediated cell death and cytotoxicity. | 2011-07-07 |
20110165099 | Oxidation Resistant Dentifrice Compositions - Low water tooth pastes contain a variety of plant extracts. The oral or dentifrice compositions containing humectants, abrasive compounds, and a variety of plant extracts, such as rosemary and green tea extracts, along with an additional antioxidant component. Examples of antioxidants include stannous compounds, sodium meta-bisulfite, BHT, ammonium sulfate, and potassium stannate. The compositions are resistant to browning. The invention also provides methods for promoting oral health of a subject animal comprising applying a composition as discussed above to the oral surfaces of the animal. | 2011-07-07 |
20110165100 | COMPOSITIONS COMPRISING AVERMECTIN/AZELAIC ACID COMPOUNDS USEFUL FOR TREATING, E.G., ROSACEA - Pharmaceutical/dermatological compositions useful for the prevention/treatment of disorders of the skin, especially rosacea, contain thus effective amounts of at least one avermectin compound, e.g., ivermectin, and at least one azelaic acid compound or salt or derivative thereof, formulated into a physiologically acceptable medium therefor. | 2011-07-07 |
20110165101 | PHOTO-LABILE PRO-FRAGRANCE CONJUGATES - The present invention relates to photo-labile pro-fragrance conjugates comprising:
| 2011-07-07 |
20110165102 | COSMETIC COMPOSITION WITH IMPROVED APPLICATION TIME - The invention relates to an anhydrous cosmetic composition for making up and/or caring for the eyelashes and/or the eyebrows, comprising at least one volatile hydrocarbon solvent of C | 2011-07-07 |
20110165103 | CONDITIONING COMPOSITION FOR HAIR - The present invention is related to an aqueous conditioning composition for hair comprising at least one alkyl ester/amido alkyl amine or alkyl ester/amido alkyl quaternary amine and an aqueous emulsion of divinyldimethicone/dimethicone copolymer with an internal phase viscosity of more than 1×10 | 2011-07-07 |
20110165104 | CLEANSING COMPOSITION - An aqueous cleansing composition for keratin fibres comprises at least one amino acid surfactant and an aqueous emulsion of divinyldimethicone/dimethicone copolymer with a special viscosity. The amino acid surfactant is of the following structure | 2011-07-07 |
20110165105 | CONDITIONING COMPOSITION FOR HAIR - The present invention is related to an aqueous conditioning composition for hair comprising at least one alkyl glyceryl ether and at least one arylated silicone. Conditioning composition of the present invention can be in the form of a shampoo, cleansing—conditioning composition, or in the form of a conditioner used after washing hair with cleansing compositions. It has surprisingly been found out that a composition comprising at least one alkyl glyceryl ether and at least one arylated silicone gives hair shine, and hair treated with such a composition looks attractive and has its natural excellent shine, volume and body, elasticity, smoothness and it is easily manageable. Accordingly, the present invention is on a conditioning composition for hair comprising at least one alkyl glyceryl ether and at least one arylated silicone | 2011-07-07 |
20110165106 | CLEANSING COMPOSITION - An aqueous cleansing composition for keratin fibres comprises at least one amino acid surfactant and an aqueous emulsion of divinyldimethicone/dimethicone copolymer. The amino acid surfactant 3 of the following structure | 2011-07-07 |
20110165107 | Volume up shampoos - The invention relates to aqueous compositions comprising an anionic surfactant and a hyperbranched polyesteramide having at least one quarternized amine end-group. The compositions, in particular in the form of shampoo preparations are suited for increasing the volume of hair treated therewith. Furthermore, such compositions provide styling attributes and increase the wet-combability of hair. | 2011-07-07 |
20110165108 | COMPOSITION CONTAINING A VOLATILE LINEAR ALKANE AND A NONIONIC ASSOCIATIVE POLYMER, USEFUL FOR CONDITIONING THE HAIR - The invention relates to compositions and their use for conditioning keratin fibres, in particular the hair. The composition contains in a cosmetically acceptable medium, one or more volatile linear alkanes, and one or more nonionic associative polymers. | 2011-07-07 |
20110165109 | AGENT FOR FIBERS CONTAINING KERATIN, COMPRISING AT LEAST ONE SPECIFIC AMPHIPHILIC CATIONIC POLYMER AND AT LEAST ONE ADDITIONAL FILM-FORMING AND/OR STABILIZING POLYMER SELECTED FROM CHITOSAN AND DERIVATES THEREOF - Agent for treating fibers containing keratin, particularly human hair containing in a cosmetically acceptable carrier: (a) an amphiphilic, cationic polymer having a structural unit of formula (I), a structural unit of formula (II), a structural unit of formula (III) and a structural unit of formula (IV), wherein R | 2011-07-07 |
20110165110 | Hair Conditioning Composition And Low Energy Method Of Producing The Same - A hair conditioning composition containing very little water from which a hair conditioner can be easily produced by diluting with water, and a low energy production method thereof. A hair conditioning composition including (a) 10 to 90% by mass of specifically structured higher alcohols and/or derivatives thereof, (b) 5 to 35% by mass of cationic surfactant, and (c) a polyhydric alcohol and/or polyethylene glycol having a melting point of 70° C. or less, wherein the melting point of a gel which is formed from (a) and (b) in the composition is 70° C. or less, the water content is 10% by mass or less, and the molar ratio of (a) to (b) is 2.5 or more to less than 6.0. Also, a low energy method of producing a hair conditioner by melting the hair conditioning composition under heating at the temperature of the melting point of gel or more to 70° C. or less, and diluting it with water in an amount of 3 to 15 times by mass. | 2011-07-07 |
20110165111 | POLYMER CONJUGATES OF NESIRITIDE PEPTIDES - The invention provides nesiritide that is chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of nesiritide not attached to the water-soluble oligomer. | 2011-07-07 |
20110165112 | POLYMER CONJUGATES OF C-PEPTIDES - The invention provides pro insulin c-peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer. | 2011-07-07 |
20110165113 | POLYMER CONJUGATES OF V681-LIKE PEPTIDES - The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer. | 2011-07-07 |
20110165114 | DRUG DELIVERY COMPOSITION - There is provided a non-water soluble drug delivery composition comprising a conjugate and a polymer matrix wherein exposure of the composition to electromagnetic radiation at a suitable pre-determined wavelength and intensity induces release of the active ingredient from the composition. The conjugate is attached to the polymer matrix through non-covalent interactions. There is also provided a drug delivery apparatus formed from the drug delivery composition. | 2011-07-07 |
20110165115 | SYNERGISTIC ATTRACTANTS FOR PESTIFEROUS SOCIAL INSECTS - An insect attractant composition is disclosed. The composition includes a volatile insect attractant chemical blend comprising acetic acid and one or more compounds selected from the short chain alcohol group chosen from among methyl-1-butanol, isobutanol, and 2-methyl-2-propanol; and one or more homo- or mono-terpene herbivore-induced plant volatiles chosen from among (E)-4,8-dimethyl-1,3,7-nonatriene, (Z)-4,8-dimethyl-1,3,7-nonatriene, 4,8,12-trimethyl-1,3E,7E,11-tridecatetraene, trans-β-ocimene, cis-β-ocimene, trans-α-ocimene, cis-α-ocimene, and any combination thereof. The composition may be useful to attract one or more insect species, including, but not limited to, wasps, hornets, and yellowjackets, to a location or trap. | 2011-07-07 |
20110165116 | PHARMACEUTICAL COMPOSITIONS COMPRISING CCL2 AND USE OF SAME FOR THE TREATMENT OF INFLAMMATION - A method of treating an inflammation in a subject thereof is provided. The method comprising administering to the subject a therapeutically effective amount of CCL2, thereby treating the inflammation. Also provided are pharmaceutical compositions and unit dosage forms which comprise CCL2 for the treatment of inflammation. | 2011-07-07 |
20110165117 | IMMUNOGENIC PEPTIDES AND METHODS OF USE - The PAGE4 gene is expressed in reproductive tissues, and is expressed in reproductive cancers, such as prostate cancer, uterine cancer, and testicular cancer. Immunogenic PAGE4 polypeptides are disclosed herein, as are nucleic acids encoding the immunogenic PAGE4 polypeptides, vectors including these polynucleotides, and host cells transformed with these vectors. These polypeptides, polynucleotides, vectors, and host cells can be used to induce an immune response to PAGE4. Diagnostic methods to detect PAGE4 are also described. | 2011-07-07 |
20110165118 | 3-HETEROCYCLIC SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to 3-Heterocyclic Substituted Indole Derivatives, compositions comprising at least one 3-Heterocyclic Substituted Indole Derivative, and methods of using the 3-Heterocyclic Substituted Indole Derivatives for treating or preventing a viral infection or a virus-related disorder in a patient. | 2011-07-07 |
20110165119 | TELAPREVIR DOSING REGIMEN - This invention relates to the use of specific dosing regimens of telaprevir in combination with peg-IFN and RBV in the treatment of HCV patients, wherein the treatment comprises (a) a lead-in phase of administering to the subject pegylated interferon and ribavirin, and (b) a treatment phase of administering to the subject a combination of telaprevir, pegylated interferon and ribavirin. | 2011-07-07 |
20110165120 | INHIBITORS OF SERINE PROTEASES - The present invention relates to compounds of formula I: | 2011-07-07 |
20110165121 | USE OF PEGYLATED TYPE III INTERFERONS FOR THE TREATMENT OF HEPATITIS C - Methods for treating human patients infected with the hepatitis C virus using pegylated Type III Interferons (IL-28A, IL-28B and IL-29) alone or in combination with other antiviral agents. | 2011-07-07 |
20110165122 | METHOD FOR TARGETED AND SUSTAINED ANTIVIRAL THERAPY - Compounds compositions and methods of modulating the immune response are provided. The method uses fusion proteins of a cytokine and an antibody to potentiate the action of the cytokine. | 2011-07-07 |
20110165123 | 5' TRIPHOSPHATE OLIGONUCLEOTIDE WITH BLUNT END AND USES THEREOF - The present invention provides an oligonucleotide which is capable of activating RIG-I and inducing an anti-viral, in particular, an IFN, response in cells expressing RIG-I. The present invention further provides an oligonucleotide which is capable of activating RIG-I and which has target gene-silencing activity. The oligonucleotide of the present invention has a double-stranded section of at least 19, preferably at least 21 bp, at least one 5′ triphosphate, and at least one blunt end which bears a 5′ triphosphate. The present invention further provides the use said oligonucleotide for inducing an anti-viral, in particular, an IFN, response in vitro and in vivo. The present invention additionally provides the use of said oligonucleotide for preventing and/or treating diseases or conditions such as infections, tumors/cancers, and immune disorders. | 2011-07-07 |
20110165124 | METHODS FOR DIAGNOSING OR PREDICTING HEPATITIS C OUTCOME IN HCV INFECTED PATIENTS - The present invention relates to in vitro methods of determining a susceptibility to non-response to a hepatitis C treatment or a susceptibility to spontaneous hepatitis C clearance in a subject infected with hepatitis C. | 2011-07-07 |
20110165125 | METHODS FOR ENHANCING ENERGY METABOLISM - The invention provides methods for one or more of enhancing energy metabolism, promoting healthy energy metabolism, maintaining healthy energy metabolism, preventing conditions that result in a decline or deficiency in energy metabolism, treating conditions that result in a decline or deficiency in energy metabolism, and preventing the accumulation of excess body fat in animals without reducing energy intake by the animals. The methods comprise administering isoflavones to the animals, preferably in amounts of from about 0.001 to about 10 g/kg/day. | 2011-07-07 |